Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$50.46
-3.4%
$54.33
$39.97
$72.83
$9.85B0.952.57 million shs2.15 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$56.45
-2.4%
$54.29
$42.01
$70.51
$7.12B1.151.75 million shs1.11 million shs
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$139.10
+1.1%
$112.10
$90.29
$139.53
$2.65B0.84119,379 shs347,058 shs
Repligen Corporation stock logo
RGEN
Repligen
$116.25
-6.3%
$124.65
$102.97
$182.52
$6.97B1.11726,248 shs1.03 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-2.72%-2.08%-0.63%+25.57%+5.75%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-0.34%+0.31%+8.85%-1.67%+5.59%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
+6.13%+10.07%+22.24%+31.06%+36.11%
Repligen Corporation stock logo
RGEN
Repligen
+3.58%-7.43%+2.50%-4.58%-6.25%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
4.6942 of 5 stars
3.55.00.04.72.72.50.6
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.9625 of 5 stars
3.14.00.04.42.92.54.4
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.5289 of 5 stars
1.51.00.04.42.13.31.9
Repligen Corporation stock logo
RGEN
Repligen
4.7212 of 5 stars
4.31.00.04.53.01.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
2.95
Moderate Buy$70.5039.71% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.17
Hold$62.7011.07% Upside
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
3.00
Buy$147.175.80% Upside
Repligen Corporation stock logo
RGEN
Repligen
2.69
Moderate Buy$170.7546.88% Upside

Current Analyst Ratings Breakdown

Latest LGND, EXAS, RGEN, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$58.00 ➝ $60.00
7/10/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$55.00
7/8/2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$66.00 ➝ $68.00
7/8/2025
Repligen Corporation stock logo
RGEN
Repligen
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$140.00 ➝ $130.00
6/24/2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.00
6/24/2025
Repligen Corporation stock logo
RGEN
Repligen
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$150.00
5/29/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00
5/14/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.00
5/13/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
5/13/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform$47.00
5/9/2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$142.00 ➝ $145.00
(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
$2.76B3.45$5.44 per share9.27$12.98 per share3.89
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.02B6.85$4.54 per share12.43$2.86 per share19.74
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$167.13M16.05$1.62 per share85.61$43.95 per share3.16
Repligen Corporation stock logo
RGEN
Repligen
$634.44M10.29$2.91 per share39.93$35.21 per share3.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$1.03B-$5.51N/A100.9211.15-36.06%-3.75%-1.68%8/6/2025 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$444.09M$3.7615.019.080.3944.76%136.91%26.05%8/5/2025 (Estimated)
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
-$4.03M-$7.12N/A37.49N/A-73.07%-7.83%-6.92%8/5/2025 (Estimated)
Repligen Corporation stock logo
RGEN
Repligen
-$25.51M-$0.45N/A49.263.55-3.93%4.53%3.17%7/29/2025 (Estimated)

Latest LGND, EXAS, RGEN, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$0.04N/AN/AN/A$774.43 millionN/A
8/5/2025Q2 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.22N/AN/AN/A$282.66 millionN/A
8/5/2025Q2 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.54N/AN/AN/A$43.87 millionN/A
7/29/2025Q2 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.40N/AN/AN/A$174.62 millionN/A
5/8/2025Q1 2025
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
$1.23$1.33+$0.10-$2.21$37.84 million$45.33 million
5/6/2025Q1 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.98$1.11+$0.13$0.93$231.21 million$264.86 million
5/1/2025Q1 2025
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 million
4/29/2025Q1 2025
Repligen Corporation stock logo
RGEN
Repligen
$0.35$0.39+$0.04$0.10$163.65 million$169.17 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/AN/AN/AN/AN/A
Repligen Corporation stock logo
RGEN
Repligen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
0.97
2.73
2.38
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
3.13
8.39
7.30
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
N/A
5.27
5.02
Repligen Corporation stock logo
RGEN
Repligen
0.27
6.79
5.79

Institutional Ownership

CompanyInstitutional Ownership
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
88.82%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
91.28%
Repligen Corporation stock logo
RGEN
Repligen
97.64%

Insider Ownership

CompanyInsider Ownership
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
1.20%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.40%
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
7.00%
Repligen Corporation stock logo
RGEN
Repligen
1.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
7,000188.64 million186.37 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390123.22 million120.26 millionOptionable
Ligand Pharmaceuticals Incorporated stock logo
LGND
Ligand Pharmaceuticals
8019.29 million17.94 millionOptionable
Repligen Corporation stock logo
RGEN
Repligen
1,77856.18 million55.51 millionOptionable

Recent News About These Companies

Repligen Corp (RGEN) Trading Down 4.19% on Jul 18
Q1 Earnings Estimate for Repligen Issued By Leerink Partnrs
Repligen to Report Second Quarter 2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Exact Sciences stock logo

Exact Sciences NASDAQ:EXAS

$50.46 -1.75 (-3.35%)
Closing price 04:00 PM Eastern
Extended Trading
$50.46 -0.01 (-0.01%)
As of 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$56.45 -1.36 (-2.35%)
Closing price 04:00 PM Eastern
Extended Trading
$56.44 -0.01 (-0.01%)
As of 07:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Ligand Pharmaceuticals stock logo

Ligand Pharmaceuticals NASDAQ:LGND

$139.10 +1.53 (+1.11%)
Closing price 04:00 PM Eastern
Extended Trading
$139.14 +0.04 (+0.03%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Repligen stock logo

Repligen NASDAQ:RGEN

$116.25 -7.79 (-6.28%)
Closing price 04:00 PM Eastern
Extended Trading
$116.61 +0.36 (+0.31%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.